INTRODUCTION {#S1}
============

*Streptococcus pneumoniae* is a major etiologic agent of infections from mild mucosal infections such as otitis media and sinusitis to more serious infections like pneumonia and meningitis ([@R1]). This organism is the cause of 700,000 to 1,000,000 annual deaths in children aged 1 to 59 months, which is about 11% of all deaths of children in this age group ([@R2]). The appearance of antibiotic resistance in *S. pneumoniae* has raised a global concern over the past three decades. Antimicrobial resistance among this microorganism is a serious problem especially for frequently utilized beta-lactams, macrolides and fluoroquinolones ([@R3],[@R4]). Emergence of multi-resistance isolates and the potential spread of these organisms have crucial implications for the treatment and clinical outcome of the patients ([@R5]--[@R8]). With recently different bacterial susceptibility patterns introduced from various geographical areas, it is essential to find the antimicrobial patterns in order to control the spread of resistant bacteria ([@R9]). This is more significant in developing countries where a severe misuse of antibiotics at all levels, as a result of the over-the-counter services without prescription in many cases, has been observed ([@R10],[@R11]). There are some reports of concerning the antimicrobial susceptibility patterns of *S. pneumoniae strains* in Iran ([@R6],[@R10],[@R12]). However, no valid data to show the changes of the antimicrobial susceptibility during different years is available. In addition, there is no valid data with a large sample size from tertiary center hospital which have the cases from different areas of Iran.

This study was conducted to determine the antimicrobial susceptibility of *S. pneumoniae* isolated from patients in Children´s Medical Center Hospital (CMC) during 2001 to 2011.

MATERIALS AND METHODS {#S2}
=====================

We retrospectively reviewed laboratory records of all patients with S*. pneumoniae* positive culture during 2001-2011 in CMC Hospital. This hospital is one of the referral tertiary centers of Tehran University of Medical Sciences and patients are admitted from all regions of Iran representing a wide spectrum of socioeconomic levels. Data of microorganisms and antibacterial susceptibility were obtained from the records of clinical microbiology laboratory were filled out on a prepared datasheet.

Isolation and identification of *S. pneumoniae* {#S3}
-----------------------------------------------

Blood was inoculated into a single 20-mL bottle of brain heart infusion broth with sodium polyanethol sulphonate and was incubated at 37°C in air for 7 days, with routine subcultures onto sheep blood agar in 5% CO~2~ at 24 hour, 48 hour, and 7 days. Turbid bottles were examined by Gram statining and subcultured onto appropriate media. Cerebrospinal fluid was analyzed by Gram stains if the white blood cell count was \>10/mm^3^. All samples were cultured on sheep blood agar for 48 hour under aerobic and microaerophilic conditions. Organisms were identified in the microbiology laboratory of CMC Hospital using standard identification methods including alpha-haemolysis, bile solubility and optochin sensitivity ([@R13]--[@R15]).

Antimicrobial agents and susceptibility testing {#S4}
-----------------------------------------------

Antimicrobial susceptibility testing was performed using Kirby-Bauer disk diffusion method, which is the predominant assay used in Iran. Bacterial sensitivity was tested for the following antimicrobials: vancomycin, ceftriaxone, cefotaxime, cefazolin, ampicillin, chloramphenicole, oxaciilin, erythromycin, gentamicin and trimethoprim-sulfamethoxazole. The guidelines of clinical and laboratory standard institute (CLSI) was followed to determine the disk zone diameters as susceptible or resistant ([@R16]). Intermediate susceptibility to antimicrobial agents was categorized as resistant in the data analysis and presentations. Quality control organisms were used in the CMC microbiology laboratory to ensure accurate performance of the laboratory tests.

Data analysis was performed using SPSS, version 17 (Inc, Chicago IL, USA). Time series analyses were used to predict the changes of the variables during the time.

RESULTS {#S5}
=======

During the time period of 2001--2011 (11 years), a total of 194 *S. pneumoniae* isolates were collected in CMC Hospital. Nearly two-thirds of the total isolates (n=126 \[65%\]) were obtained from bloodstream infections, and the remaining isolates were cultured from sputum (n=19 \[10%\]), eye (n=16 \[8%\]), CSF (n=13 \[7%\]), ascites (n=6 \[3%\]), ear (n=6 \[3%\]) and others (n=8 \[4%\]).

The overall susceptibility of *S. pneumoniae* to different antibiotics was as: 100% to vancomycin, 88% to ceftriaxone, 87% to cefotaxime, 78% to cefazolin, 76% to ampicillin, 70% to chloramphenicol, 54% to penicillin, 49% to erythromycin, 37% to gentamicin and 28% to trimethoprim-sulfamethoxazole.

Variable susceptibility profiles for different antibiotics were observed over the 11 years, the prevalence of susceptibility to penicillin decreased from 78% (23 of 30) in 2001 to 32% (13 of 45) in 2011. In the same time period, susceptibility to erythromycin declined from 75% (12 of 16) in 2001 to 35% (15 of 43) in 2011 and susceptibility to chloramphenicol started to decrease from 94% (15 of 16) to 55% (23 of 42). In addition, during these couple of years, susceptibility to ampicillin declined from 70% (14 of 20) to 62% (26 of 42). Beside this, susceptibility to ceftriaxone started to fall from 100% (8 of 8) to 87% (35 of 40) and susceptibility to sulfametoxazole came down from 57% (10 of 18) to 40% (17 of 42).

Time series analysis of the 5 antibiotics of penicillin, erythromycin, chloramphenicol, ceftriaxone, and trimethoprim-sulfamethoxazole showed an overall decreasing trend for *S. pneumoniae* susceptibility during 2001 to 2011 and even forecasting prediction for 2016 ([Fig. 1](#F1){ref-type="fig"}-[5](#F5){ref-type="fig"}). Individual susceptibility to these 5 antibiotics has declined during 2001-2011 by 2.4, 2.1, 1.7, 1.1, and 1.4 times. On the other hand, cefotaxime resistance increased from initially low levels in 2002 to reach a plateau from 2005 onward; however, after decreasing slightly in 2006 this rate was stable until 2008 and the rate increased again in 2011. Susceptibility of *S. pneumoniae* to gentamicin was 14% (3 of 21) in 2001, 33% (7 of 21) in 2003, 15% (2 of 13) in 2005, 28% (8 of 29) in 2010, and 49% (21 of 43) in 2011.

Susceptibility of *S. pneumoniae* to ampicillin was different during various years; it was about 70% in 2001 but it did not stay stable very long time and the percentages declined to around 55% in 2002 and 2003. Further on, the percentages increased to 85% in 2005 and stayed steady until 2010, finally the percentage dropped to 62% (26 of 42) in 2011. Concurrent resistance to ampicillin and erythromycin was not detected in 2001 but reached to 18.4% (7 of 38) in 2011. At the same period of time, ampicillin-chloramphenicol resistance was starting to rise from zero to 10.5% (4 of 38) as well as ampicillin-ceftriaxone resistance which was increased from zero to 8% (3 of 37). Moreover erythromycin-ceftriaxone resistance was starting to increase from zero to 5.2% (2 of 38) and ceftriaxone-chloramphenicol resistance went up from zero to 7.6% (3 of 39). Moreover, erythromycin-chloramphenicol resistance was raised dramatically from zero to 45% (18 of 40).

DISCUSSION {#S6}
==========

This study reveals the development of antibiotic resistance of *S. pneumoniae* in CMC Hospital over an 11-year period (2001--2011). Overall, the susceptibility rate to 5 main antibiotics of penicillin, erythromycin, chloramphenicol, ceftriaxone and trimethoprim-sulfamethoxazole has shown striking changes through the 11 years from high levels in 2001 to low levels in 2011.

International studies by Asian Network For surveillance of Resistant Pathogens (ANSORP) documented extremely high prevalence of penicillin and erythromycin resistance among clinical cases of *S. pneumoniae* in Korea, Japan, Thailand, Taiwan and Sri Lanka ([@R5]). The increase in prevalence of antimicrobial resistant in *S. pneumoniae* is related to increase of invasive *S. pneumoniae* infections in children and more clinical failures of antimicrobial treatments ([@R5],[@R17]). A study by Mera *et al,* reported a decline in *S. pneumoniae* susceptibility during 1992-2001 in the United States ([@R18]). Another study by Whitney *et al.* reported a similar reduction during 1995-1998 in United States ([@R19]). This study found that if the upsurge of antibiotics usage continues, we might lose the efficacy of important antibiotics such as penicillin, erythromycin and trimethoprim-sulfamethoxazole by 2016.

In our study the susceptibility to penicillin was 32% in 2011 that was similar to other reports from north, central America and Asia ([@R20]--[@R22]) while there are some reports that shows higher susceptibility for this antibiotic ([@R12], [@R23]). According to ANSORP reports, although penicillin non-susceptibility (40--60%) is common in Asia, reduced susceptibility could not be related to a worse clinical outcome ([@R5],[@R24]). Sangthawan *et al.* reported that prior antibiotic use was significantly associated with penicillin resistance in *S. pneumoniae* isolates in Thailand but this outcome was not related to in vitro penicillin susceptibility pattern ([@R24]).

Despite various reports on penicillin resistance in pneumococcus, it is difficult to demonstrate a clear relationship between penicillin resistance and clinical failure. It can be explained because the susceptibility breakpoints were initially established on the basis of achievable levels of this antibiotic in the cerebrospinal fluid while most pneumococcal infections occur in the lung or the bloodstream ([@R25]).

Similar to other studies, we found the overall susceptibility to vancomycin as 100%. That means the most resistant strains of *S. pneumoniae* still remain sensitive to this antibiotic ([@R12], [@R19], [@R26]). Our data showed that cefotaxime and ceftriaxone ([Fig 4](#F4){ref-type="fig"}) which recommended for empiric pneumonia therapy still have good effect due to low prevalence of resistance. The overall susceptibility to cephalosporins was 88% to ceftriaxone and 87% to cefotaxime but the important point is that the susceptibility to cephalosporins was about 100% in 2001 and decreased to 88% in 2011 and the forecasting analysis shows that it would be lower in the future.

Harrison *et al.* found the susceptibility of 86% to 95% for ceftriaxone in the United States (27). A study by Kohanteb *et al.* reported a higher susceptibility rate for cephalosporins (cefotaxime 96% and ceftriaxone 94%) in Iran ([@R12]). Moreover, ANSORP reported 92% susceptibility to ceftriaxone in Asia ([@R5]).

Macrolides are considered as the alternative to β-lactams in the treatment of *S. pneumoniae*. Although ANSORP reported very low erythromycin susceptibility rate in Asian countries including 8% in Vietnam, 14% in Taiwan, 19% in Korea and 26% in China ([@R5]), it should be highlighted that macrolide resistance among pneumococci appears to be increasing in prevalence. In this study the overall susceptibility to erythromycin was 49% which was dramatically decreased from 75% in 2001 to 35% in 2011. Further on, it is predicted to be under the 20% in 2016 ([Fig. 2](#F2){ref-type="fig"}).

This study identifies unstable patterns of resistance to available antimicrobial drugs during 11 years. Continued epidemiological surveillance appears to be prudent practice to guide effective chemotherapy. Moreover, it would be an important key to consider antimicrobial stewardship as an essential factor to prevent the development of antimicrobial resistance.
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